Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.290 +0.210 (+10.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q1 2025 Results on May 15
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), 
Via Benzinga
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter
Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11,... 
Via Stocktwits
Topics Intellectual Property Law Enforcement Lawsuit
Exposures Financial Intellectual Property Legal
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100
Via Investor Brand Network
Exposures Product Safety
$4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Promising Treatment Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
Amazon.com To $253? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP
Via Get News
Exposures Product Safety
$300 Million in Milestones; Double-Digit Royalties; LOI with Neurospa for Expansion of International Psychiatry Clinics; NDA Filed with FDA on New Drug: NRx Pharmaceuticals: (Stock Symbol: NRXP)
Via Get News
Exposures Product Safety
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 
Via Stocktwits
What's Going On With NRX Pharmaceuticals Stock Tuesday?
NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics. 
Via Benzinga
Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations, Plus New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP
Via Get News
Exposures Product Safety
What's Going On With NRX Pharmaceuticals Stock Thursday?
NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute. 
Via Benzinga
Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading. 
Via Benzinga
New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects Over 13 Million Americans Each Year: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Via Get News
Exposures Product Safety
Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20
Via Investor Brand Network
Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance
Exposures Legal Regulatory
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Regulatory Compliance Retirement
Exposures Legal Pension Regulatory
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to... 
Via PRLog
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.